Inhibitor Therapeutics, Inc.
INTIOTCHealthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $0 | $0 |
| Operating income | −$3.4M | −$3.7M | −$3.4M | −$657,926 | −$325,395 | −$1.1M |
| Net income | −$3.3M | −$3.3M | −$3.0M | $12.1M | −$298,632 | −$1.1M |
| Total assets | $2.5M | $5.7M | $8.9M | $12.0M | $58,784 | $131,759 |
| Total liabilities | $3.8M | $3.7M | $3.7M | $3.7M | $3.7M | $3.5M |
| Equity | −$1.3M | $2.0M | $5.3M | $8.3M | −$3.6M | −$3.4M |
| EPS (diluted) | $-0.02 | $-0.02 | $-0.02 | $0.03 | $0.00 | — |
| Shares out. | 172.3M | 172.0M | 171.8M | 376.9M | 375.9M | 370.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- —
- Return on equity
- 255.5%
- Return on assets
- −131.4%
- Return on capital (ROCE)
- −196.4%
- Liabilities / assets
- 151.4%
- Debt / equity
- —
- Book value / share
- $-0.01
- Revenue growth (YoY)
- —
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Altman Z″ (distress)
- -77.08distress
- Accruals / assets
- −2.7%clean
- Piotroski F-Score
- 1/7weak
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 3 severe● 2 warning● 2 good- Negative shareholder equity
- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- High leverage (liabilities > 70% of assets)
- Negative operating cash flow
- Strong return on equity (>15%)
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Kmissed a reporting deadline ↗Mar 31, 2014
- NT 10-Qmissed a reporting deadline ↗May 15, 2013
- NT 10-Kmissed a reporting deadline ↗Apr 1, 2013
- NT 10-Qmissed a reporting deadline ↗Nov 13, 2012
- NT 10-Qmissed a reporting deadline ↗Aug 14, 2012
- NT 10-Kmissed a reporting deadline ↗Mar 30, 2012
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 17,114 | 1.0 | +100.0% |
| Apr 15, 2026 | 632 | 1.0 | -97.2% |
| Mar 31, 2026 | 22,435 | 1.1 | -6.3% |
| Mar 13, 2026 | 23,934 | 1.0 | +82.1% |
| Feb 27, 2026 | 13,144 | 1.0 | +7.3% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Regulation FD disclosureApr 1, 2026
- Other material eventApr 1, 2026
- Entered a material agreementFeb 24, 2026
- Entered a material agreement · Director / officer changeOct 27, 2025
- Entered a material agreement · Other material eventDec 14, 2023
- Director / officer change · Amended charter or bylawsOct 18, 2023
- Director / officer change · Amended charter or bylawsAug 29, 2023
- Director / officer changeMay 31, 2023
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗Event-driven situations (1)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.